WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Hong Kong stocks rebounded from a four-month low after China’s securities regulator pledged to stabilise the market after a wobbly start to the year. The Hang Seng Index rose 1.4 per cent to 19,141.13 ...

WuXi AppTec announced late yesterday that the Shanghai-based company had pared its stake in WuXi XDC Cayman through two block ...

We've identified the following companies as similar to WuXi Biologics (Cayman) Inc. because they operate in a related industry or sector. We also considered size, growth, and various financial ...

We've identified the following companies as similar to WuXi Biologics (Cayman) Inc. because they operate in a related industry or sector. We also considered size, growth, and various financial metrics ...

1 Day WXXWY 4.90% DJIA 0.38% S&P 500 -0.41% Health Care/Life Sciences 0.43% ...

WuXi Biologics (Cayman) Inc. has announced a change in its principal place of business in Hong Kong, effective January 10, 2025, to Room 1910, 19/F, Lee Garden One, Causeway Bay. This relocation ...

Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties.

CHMP has granted Eisai Europe and Biogen a positive opinion for the use of their monoclonal antibody therapy in treating early Alzheimer’s disease.